OPN-305

DRUG3 trials

Sponsors

Opsona Therapeutics Ltd.

Conditions

Delayed Graft FunctionMyelodysplastic Syndrome

Phase 1

A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

CompletedNCT02363491

Opsona Therapeutics Ltd.Myelodysplastic Syndrome

Start: 2015-01-31End: 2018-12-31Updated: 2019-01-28

Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome

CompletedNCT03337451

Opsona Therapeutics Ltd.Myelodysplastic Syndrome

Start: 2018-02-27End: 2019-01-10Updated: 2019-01-28

Phase 2

Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function

CompletedNCT01794663

Opsona Therapeutics Ltd.Delayed Graft Function

Start: 2012-10-31End: 2016-06-30Updated: 2017-02-16